Study of CTX-471 for advanced neuroendocrine tumors
Part of Cancer clinical trials.
This study tests an immunotherapy drug (CTX-471) for people with a specific type of advanced neuroendocrine tumor that has grown after chemotherapy. The goal is to see if the drug can help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your tumor is a grade 3 neuroendocrine tumor or neuroendocrine carcinoma (a fast-growing type).
- Your tumor tests positive for a marker called NCAM.
- You have already tried at least one chemotherapy treatment.
- You are in generally good health (able to do light activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ADCT-701 for people with certain rare cancers (neuroendocrine tumors, adrenal cancer, or a type of nerve tumor) that have come back or spread. The drug is an antibody-drug conjugate, which works like a targeted missile to kill cancer cells while trying to spare healthy ones.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This Phase 1 study tests how well Lutathera combined with ASTX727 can treat neuroendocrine tumors. It looks mainly at whether the combination can be given safely and effectively for people whose tumors have grown or not tolerated standard first treatment.
This trial tests whether adding three medicines—sintilimab, IBI310, and surufatinib—can control advanced, high-grade neuroendocrine tumors (that cannot be removed by surgery or have spread). It may help if your cancer has grown despite standard treatment, or if you cannot take standard treatment due to side effects.
This study tests cabozantinib, a targeted therapy that blocks tumor growth, in people with advanced neuroendocrine tumors who have already tried other treatments. It may offer a new option if your doctor plans to use this drug.
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
Hear when a new Neuroendocrine Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.